News

Takeda Pharmaceuticals’ TAK-226-3001 trial, taking place at King’s College Hospital in London, is a phase 3 study comparing a novel treatment, elritercept, against the current standard treatment, epoetin alfa, for anaemia in adults with lower-risk MDS. The trial is set to begin in September and aims to recruit 300 patients, some of whom may remain…

Professor Shahram Kordasti and Professor Mieke Van Hemelrijck from King’s College London have been awarded a £1 million grant, funded by the Medical Research Council, to lead a major international research effort that could revolutionise how MDS is understood and treated. This funding will power an international collaboration called the i4MDS Consortium (International Integrative Innovative…

This summer Orca Bio announced that the U.S. Food and Drug Administration (FDA) has approved TREGZI™ (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq; Orca-T®). TREGZI is a precision-engineered cell therapy for use in matched-donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic reconstitution, and is used to improve…

AIPaSiM – Italian Association for Patients with Myelodysplastic Syndrome has among its targets to help patients acquire more consciousness of all the aspects, not just clinical, of their pathology. At the heart of Scientific Art in Hematology – The Sense of Images is a simple but powerful idea: transforming hematologic pathology from something abstract and…

British Columbia (Canada) is facing criticism for refusing to fund Luspatercept, a medication used to treat MDS that is publicly covered in every other Canadian province. Luspatercept is a medication that helps the body produce more mature red blood cells, reducing or eliminating the need for blood transfusions and improving quality of life for many…

Dr Kevin Rouault-Pierre and his team at Barts Cancer Institute, Queen Mary University of London, have been awarded a £1 million Cancer Research UK grant to launch a new clinical trial for people living with MDS. In partnership with Dr Onima Chowdhury at the MRC Weatherall Institute of Molecular Medicine and Oxford University Hospitals, and…

The MDS Alliance is pleased to share with you the final report of the 2024 global survey. The focus for ‘The MDS Global Survey 2024’ was ‘access to care’ and this was to be delivered with the support of Picker, an international charity working across health and social care. The main survey topic was selected…

The EU Clinical Trials website provides a comprehensive map for searching clinical trials across Europe. Users can easily navigate through various trials by filtering options such as disease area, trial phase, and location. The interactive map allows for a visual representation of ongoing studies, making it easier for patients, researchers, and healthcare professionals to find…

More than 300 million people worldwide are living with a rare disease. Rare Disease Day is a global campaign that aims to raise awareness and offer support for those on a rare medical journey, including rare cancers such as MDS. This event takes place annually on the last day of February, which this year falls…

The Global MDS Survey 2024/2025 is closed. We thank everyone who participated and helped strengthen the voices of MDS patients. We are proud to have increased the number of participants in this survey. There were over 700 completed questionnaires. We are now working on the analysis and evaluation and will provide the report here as…